

Atty Docket No. 15280W-003000

PTO FAX NO.: 703-872-9306  
571-273-0609

RECEIVED  
CENTRAL FAX CENTER

FEB 22 2005

ATTENTION: Examiner Badio  
Group Art Unit 1616

**OFFICIAL COMMUNICATION****FOR THE PERSONAL ATTENTION OF****EXAMINER BADIO****CERTIFICATION OF FACSIMILE TRANSMISSION**


I hereby certify that the following documents, in re Application of Hyun K. Kim *et al.*, Application No. 09/526,855, filed March 17, 2000, for STRUCTURAL MODIFICATION OF 19-NORPROGESTERONE I: 17-ALPHA-SUBSTITUTED-11-BETA-SUBSTITUTED-4-ARYL AND 21-SUBSTITUTED 19-NORPREGNADIENEDIONE AS NEW ANTIPROGESTATIONAL AGENTS, is being facsimile transmitted to the Patent and Trademark Office on the date shown below.

Documents Attached

1. Transmittal Form

Number of pages being transmitted, including this page: 3 4

Dated: February 22, 2005

  
Linda Shaffer

**PLEASE CONFIRM RECEIPT OF THIS PAPER BY  
RETURN FACSIMILE AT (415) 576-0300**

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, 8th Floor  
San Francisco, CA 94111-3834  
Telephone: (415) 576-0200, Fax: (415) 576-0300  
60427099 v1

I hereby certify that this correspondence is being deposited by facsimile to  
Art Unit 1616 at 703-872-9306

**PATENT**  
Attorney Docket No.: 15280W-003000  
Client Ref. No.: E-155-1999

On 2-22-05

TOWNSEND and TOWNSEND and CREW LLP

By: Gilda Shaffer

RECEIVED  
CENTRAL FAX CENTER

FEB 22 2005

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

Hyun K. Kim *et al.*

Application No.: 09/526,855

Filed: March 17, 2000

For: STRUCTURAL MODIFICATION  
OF 19-NORPROGESTERONE 1: 17-  
ALPHA-SUBSTITUTED-11-BETA-  
SUBSTITUTED-4-ARYL AND 21-  
SUBSTITUTED 19-  
NORPREGNADIENEDIONE AS NEW  
ANTI-PROGESTATIONAL AGENT

Customer No.: 20350

Confirmation No. 3023

Examiner: Barbara P. Badio

Technology Center/Art Unit: 1616

CORRECTED AMENDMENT AFTER  
ALLOWANCE UNDER 37 CFR § 1.312(a)

**Mail Stop AF**

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

In response to a telephone inquiry of Examiner Badio in which it was noted that there was a typographical error in the "Amendments to the Specification" in the previously filed Amendment After Allowance, Applicants amend the above-identified application as follows:

**Amendments to the Specification** begin on page 2 of this paper.

**Remarks/Arguments** begin on page 3 of this paper.